Associate Editors-in-Chief

Tung-Sung Tseng, DrPH, MS, CHES/MCHES (Public Health)

Associate Professor, Behavioral and Community Health Sciences, LSUHSC School of Public Health, New Orleans, LA, USA

Dr. Tung-Sung Tseng, is Charles L. Brown, Jr., MD, Endowed Professor of Health Promotion and Disease Prevention in Community Health Science & Policy at School of Public Health, Louisiana State University Health Sciences Center in New Orleans. Dr. Tseng is a Certified Health Education Specialist (CHES) / Master Certified Health Education Specialist (MCHES) and serves as editor, associate editor and editor board member for 7 more professional journals. He is an active member of the Tobacco Control Initiative (TCI), Design and Analysis Core, LSU’s Improving Clinical Outcomes Network, Health Care Services Division- Innovation Resource Center (HCSD-IRC) and Stanley S. Scott Cancer Center. His primary research interests include tobacco control, childhood obesity, gene-environment interaction, community-based participatory research (CBPR), risk behavioral patterns, health promotion interventions and evaluations, health disparities, and cancer prevention among ethnic minorities and underserved populations. As PI or co-Investigator on several university- and NIH-funded grants, he develops effective intervention approaches and measures of risk behaviors, social determent of health, and other psychosocial factors relevant to the cancer/obesity, and by establishing strong ties with genetic and behaviors intervention as documented in the professional publications. He has published three book chapters and more than 100 peer review articles in leading journals in the field of tobacco, cancer, obesity and health disparities.

Associate Editor-in-Chief 
Terms of Appointment: September 2019 - August 2024; September 2024 - December 2026

Updated on October 11, 2024

Jaime L. Schneider, MD, PhD

Research interests: oncogene-driven lung cancers, acquired resistance to targeted therapies, tumor metabolism

Dr. Jaime L. Schneider is a thoracic oncologist and physician–scientist based in Boston, MA. She earned her M.D./Ph.D. at Albert Einstein College of Medicine in New York, and she completed her internal medicine residency at Massachusetts General Hospital and fellowship in Medical Oncology at Dana-Farber Cancer Institute. She is a practicing medical oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School and her research program is in the Division of Molecular and Cellular Oncology at DFCI, where she is the principal investigator of a lab focused on targeted therapies and mechanisms of resistance in lung cancer.

As a basic/translational investigator, Dr. Schneider’s research focuses on non-small cell lung cancer, with a specific interest in cancers that harbor actionable oncogenic driver alterations. Using clinical specimens and patient-derived models, she is using integrative metabolomics approaches to identify resistance mechanisms in oncogene-driven lung cancer. She is investigating whether specific onco-genotypes in lung cancer confer metabolic vulnerabilities and how metabolic reprogramming underlies resistance to targeted therapies. Dr. Schneider has authored publications in Cell, Nature Cancer, Cell Metabolism, Nature Communications, NPJ Precision Oncology, The Oncologist, and JTO Clinical and Research Reports. Her work on ALK-positive lung cancer has been highly cited, reflecting her contributions to advancing precision oncology. As a lab-based physician–scientist, she integrates patient care with translational research to accelerate the development of novel therapies for patients with lung cancer.

Associate Editor-in-Chief
Terms of Appointment: April 2025 - March 2027

Hooman Soleymani Majd, MD

Mr Hooman Soleymani Majd started his Obstetrics and Gynaecology career in London, before moving to Oxford where he completed his structured postgraduate training programme. During the course of training he obtained his membership of the Royal College of Obstetricians and Gynaecologists (MRCOG), which culminated in a Certificate of Completion of Training (CCT) in Obstetrics and Gynaecology. Mr. Soleymani majd completed a further three years of Sub-Specialty Training in Gynaecological Oncology at the Churchill Cancer Centre in Oxford. He is also a BSCCP accredited Colposcopist and trainer, as well as a member of the British Gynaecological Cancer Society (BGCS).

He is an accomplished and experienced surgeon, performing numerous complex radical laparoscopic and open surgeries every year. He has a special interest in performing ultra-radical surgery for ovarian cancer; his skill set includes upper abdominal surgery, liver mobilisation and diaphragmatic reconstruction. Mr Soleymani majd also has a particular surgical interest in treating patients with Placenta Accreta Spectrum (PAS) and is a founding member of the OxPAT group. Mr Soleymani Majd has active involvement in teaching registrars/fellows and medical students from Oxford University. He is part of an Oxford research group that has a special interest in new developments in surgical techniques in ultra-radical surgery for advanced ovarian cancer, he has published many papers and been invited to speak at a number of international congresses.

He is on the editorial board of Current Problems in Cancer: Case Reports, Gynecology and Pelvic Medicine (GPM) and the Journal of Obstetrics, Gynecology and Cancer Research (JOGCR). He is also a reviewer for Cereus, BMJ case reports, European Journal of Gynaecology Oncology (EJGO) and Frontiers in Oncology. Mr Soleymani majd is an Honorary Senior Clinical Lecturer in Gynaecological Oncology surgery at Oxford University and works as a Consultant in Gynaecological Oncology at the Churchill Hospital, Oxford, and has been in post since 2016.

Associate Editor-in-Chief
Terms of Appointment: January 2025 - December 2026